212 related articles for article (PubMed ID: 38376624)
21. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer: cardiovascular mortality and androgen deprivation.
Basaria S
Nat Rev Urol; 2009 May; 6(5):252-3. PubMed ID: 19424172
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.
Carneiro A; Sasse AD; Wagner AA; Peixoto G; Kataguiri A; Neto AS; Bianco BA; Chang P; Pompeo AC; Tobias-Machado M
World J Urol; 2015 Sep; 33(9):1281-9. PubMed ID: 25387877
[TBL] [Abstract][Full Text] [Related]
25. Contemporary role of androgen deprivation therapy for prostate cancer.
Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
[TBL] [Abstract][Full Text] [Related]
26. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
27. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
28. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
29. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
30. Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.
Lowentritt B; Fallick M; Pruett J; Jiang T; Li E; Brown B; Dufour R
Urol Pract; 2024 Jan; 11(1):154-161. PubMed ID: 37914225
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
Kim J; Freeman K; Ayala A; Mullen M; Sun Z; Rhee JW
Curr Oncol Rep; 2023 Sep; 25(9):965-977. PubMed ID: 37273124
[TBL] [Abstract][Full Text] [Related]
32. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
[TBL] [Abstract][Full Text] [Related]
33. Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk.
Melloni C; Nelson A
J Cardiovasc Transl Res; 2020 Jun; 13(3):451-462. PubMed ID: 31833002
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
35. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Greiman AK; Keane TE
Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
[TBL] [Abstract][Full Text] [Related]
36. Androgens and prostate cancer; pathogenesis and deprivation therapy.
Grossmann M; Cheung AS; Zajac JD
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
[TBL] [Abstract][Full Text] [Related]
37. [Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].
Klemm J; von Deimling M; Fisch M; Kramer G; Tilki D; Steuber T; von Amsberg G; Hengstenberg C; Shariat SF
Urologie; 2024 Mar; 63(3):262-268. PubMed ID: 37874334
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections.
Kakkat S; Pramanik P; Singh S; Singh AP; Sarkar C; Chakroborty D
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108147
[TBL] [Abstract][Full Text] [Related]
39. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.
Alwhaibi A; Alsanea S; Almadi B; Al-Sabhan J; Alosaimi FD
Aging Male; 2022 Dec; 25(1):101-124. PubMed ID: 35343371
[No Abstract] [Full Text] [Related]
40. Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer.
Gheorghe GS; Hodorogea AS; Ciobanu A; Nanea IT; Gheorghe ACD
Curr Oncol; 2021 Aug; 28(5):3331-3346. PubMed ID: 34590590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
